The Valley Desk

NCT03749187 · Interventional trial

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Overall registry status Active not recruiting

Phase 1

Conditions Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov